Verification evidence is still being completed.
PDF / print export
Froceth JSC
Vilnius, Lithuania
- Verified lead
- Agne Vaitkeviciene
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Head and Co-Founder
- 2026 technical specialization
- Advanced Therapy Medicinal Products, Adipose-Derived Cell Therapy, and Individualized Cancer Immunotherapy
- Review cycle
- 24 April 2026
- Full address
- Vilnius, Lithuania (Froceth ATMP manufacturing site)
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Craft.co company profile for Froceth naming Agne Vaitkeviciene as head and co-founder.
- Editorial note
- Lithuania's first individualized ATMP manufacturer with named head and co-founder, a Vilnius adipose tissue bank since 2014, and a 2015 ATMP manufacturing site covering anti-cancer vaccines and stem-cell preparations.
Advanced Therapy Medicinal Products, Adipose-Derived Cell Therapy, and Individualized Cancer Immunotherapy
Adipose tissue bank establishment, ATMP manufacturing site documentation, Public head and co-founder disclosure
Lithuania's first individualized ATMP manufacturer with named head and co-founder, a Vilnius adipose tissue bank since 2014, and a 2015 ATMP manufacturing site covering anti-cancer vaccines and stem-cell preparations.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Vilnius, Lithuania
Froceth JSC
Advanced Therapy Medicinal Products, Adipose-Derived Cell Therapy, and Individualized Cancer Immunotherapy · Individualized ATMP manufacturing
Lithuania's first individualized ATMP manufacturer with named head and co-founder, a Vilnius adipose tissue bank since 2014, and a 2015 ATMP manufacturing site covering anti-cancer vaccines and stem-cell preparations.
- Lead
- Agne Vaitkeviciene (verified ↗)
- Address
- Vilnius, Lithuania (Froceth ATMP manufacturing site) (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Individualized ATMP manufacturing
- Capabilities
- Individualized ATMP Manufacturing · Adipose-Derived Stem Cell Therapy · Cancer Immunotherapy and Multiple Sclerosis Programs
- Founded
- 2019
- Headcount
- 1-10
Clinical profileSTATUS: VERIFIED APRIL 2026
Agne Vaitkeviciene
Head and Co-Founder
Full addressVilnius, Lithuania (Froceth ATMP manufacturing site)
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Individualized ATMP manufacturing
Vilnius, Lithuania. Advanced Therapy Medicinal Products, Adipose-Derived Cell Therapy, and Individualized Cancer Immunotherapy. Review completed on 24 Apr 2026.
Lithuanian State Medicines Control Agency and EU ATMP framework
Adipose tissue bank establishment, ATMP manufacturing site documentation, Public head and co-founder disclosure
Advanced Therapy Medicinal Products, Adipose-Derived Cell Therapy, and Individualized Cancer Immunotherapy
Lithuania's first individualized ATMP manufacturer with named head and co-founder, a Vilnius adipose tissue bank since 2014, and a 2015 ATMP manufacturing site covering anti-cancer vaccines and stem-cell preparations.
Editorial note
Froceth is Lithuania's first individualized ATMP manufacturer with a named head and co-founder, an adipose-tissue bank established in 2014, and a 2015 Vilnius ATMP manufacturing site delivering cancer immunotherapy and regenerative programs.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Individualized ATMP Manufacturing
Adipose-Derived Stem Cell Therapy
Cancer Immunotherapy and Multiple Sclerosis Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Adipose tissue bank
Cell therapy manufacturing suites
Cryopreservation and storage infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Froceth JSC located?
- Froceth JSC operates from Vilnius, Lithuania (Froceth ATMP manufacturing site), Vilnius, Lithuania.
- Who runs Froceth JSC?
- Froceth JSC is led by Agne Vaitkeviciene, Head and Co-Founder. Verified 24 Apr 2026.
- What does Froceth JSC do?
- Lithuania's first individualized ATMP manufacturer with named head and co-founder, a Vilnius adipose tissue bank since 2014, and a 2015 ATMP manufacturing site covering anti-cancer vaccines and stem-cell preparations. Core capabilities: Individualized ATMP Manufacturing, Adipose-Derived Stem Cell Therapy, Cancer Immunotherapy and Multiple Sclerosis Programs.
Editorial context
Related technical briefs
Briefs that name Vilnius as a covered market or city.